BLAINJECTIONINJECTABLE
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
FULPHILA (pegfilgrastim-jmdb) by Viatris is colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. First approved in 2018.
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FULPHILA (pegfilgrastim-jmdb) is a biosimilar granulocyte colony-stimulating factor (G-CSF) that stimulates proliferation and differentiation of hematopoietic cells to increase neutrophil production. It is indicated for reducing the duration of severe neutropenia in cancer patients receiving myelosuppressive chemotherapy. The drug works by binding to specific cell surface receptors on hematopoietic cells, thereby triggering proliferation, differentiation, and functional activation.
$0.624MPart D
PeakFULPHILA is in peak lifecycle stage with modest Part D penetration ($624K spending across 271 claims in 2023), indicating a niche biosimilar position in the G-CSF market with limited growth signals.
Mechanism of Action
colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FULPHILA offers exposure to biosimilar commercialization, healthcare economics, and competitive positioning in oncology support, but limited opportunity for product innovation or clinical advancement. The mature lifecycle and modest market presence suggest roles are focused on maintaining market share and operational efficiency rather than growth initiatives.
Brand Manager
Worked on FULPHILA at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.